<DOC>
	<DOCNO>NCT00108095</DOCNO>
	<brief_summary>This study look range dose NK-1 receptor antagonist drug , safety effectiveness prevention PONV</brief_summary>
	<brief_title>A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-Blind , Placebo-Controlled , Dose-Ranging , Parallel Group Phase II Study Evaluate Safety , Efficacy , Pharmacokinetics Oral Neurokinin-1 Receptor Antagonist , GW67969 , When Administered With Intravenous Ondansetron Hydrochloride Prevention Post-Operative Nausea Vomiting ( PONV ) Post-Discharge Nausea Vomiting ( PDNV ) Female Subjects With Known Risk Factors PONV Who Are Undergoing Surgical Procedures Associated With Increased Emetogenic Risk</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Inclusion criterion : Females age 1855 Laparoscopic/laparotomic gynecological procedure laparoscopic gallbladder removal Exclusion criterion : Pregnant breastfeed Postmenopausal Not undergo general anesthesia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>emesis</keyword>
	<keyword>nausea</keyword>
	<keyword>post operative nausea vomit</keyword>
	<keyword>vomit</keyword>
	<keyword>PONV</keyword>
</DOC>